Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167225 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL30184358 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL23728425 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL12349812 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL711439 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL31174574 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL23728418 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL11649679 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL8346473 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL7782071 | 0.84 | OR51E2 (0.46) | PDE4ALMNAL3MBTL1TDP1OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | DOUBLERAINBOW BIOSCIENCES INC. | 2023-04-20 | — | — | US | claimed |
| EP-4121546-A1 | ETOPOSIDE GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF AS AN ANTI-CANCER DRUG | Doublerainbow Biosciences Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2021188457-A1 | ETOPOSIDE GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF AS AN ANTI-CANCER DRUG | DOUBLERAINBOW BIOSCIENCES INC. (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2021188456-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2021188459-A1 | IVACAFTOR GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF IN TREATING CYSTIC FIBROSIS | DOUBLERAINBOW BIOSCIENCES INC. (US) | 2021-09-23 | — | — | WO | claimed |
| EP-0597179-B1 | Method for processing a silver halide color photographic light-sensitive material | KONISHIROKU PHOTO IND (JP) | 1997-04-09 | — | — | EP | claimed |
| EP-0597179-A2 | Method for processing a silver halide color photographic light-sensitive material | KONICA CORPORATION (JP) | 1994-05-18 | — | — | EP | claimed |
| US-12372518-B2 | Method for stabilizing extracellular vesicles | H.U. GROUP RESEARCH INSTITUTE G. K. (JP) | 2025-07-29 | — | — | US | disclosed |
| US-12368049-B2 | Protective film agent and processing method of workpiece | DISCO CORPORATION (JP) | 2025-07-22 | — | — | US | disclosed |
| EP-4549531-A1 | ADHESIVE AGENT FOR RESIN, AND LAYERED BODY | Nihon Parkerizing Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| EP-3360578-B1 | COMPOSITE GRANULATED PRODUCT INCLUDING SUGAR OR SUGAR ALCOHOL, SWELLING BINDER, DISINTEGRATING AGENT AND HIGHLY ABSORBENT EXCIPIENT, AND METHOD FOR MANUFACTURING COMPOSITE GRANULATED PRODUCT | DAIDO CHEMICAL CORP (JP) | 2024-12-11 | — | — | EP | disclosed |
| CN-119095928-A | Adhesive for resin and laminate | 日本帕卡濑精株式会社 | 2024-12-06 | — | — | CN | disclosed |
| US-5288369-A | Mixture of higher fatty acids or salts | KAO CORPORATION (JP) | 1994-02-22 | — | — | US | disclosed |
| US-5282928-A | A reaction product of alkylene oxide with glycerol, a mixture of mono, di or triglyceride from higher fatty acid and alcohol ; discoloration, defoaming of waste paper | KAO CORPORATION (JP) | 1994-02-01 | — | — | US | disclosed |
| EP-0573927-A1 | Recycling method for photographic processing waste liquid | KONICA CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
| EP-0547796-A1 | Solid chemicals for processing silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0507325-A1 | Deinking composition and deinking method | KAO CORPORATION (JP) | 1992-10-07 | — | — | EP | disclosed |
| EP-0492507-A1 | Deinking method and deinking composition | KAO CORPORATION (JP) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | UGGT1, UGDH, GALE | PDE4A 717/4885LMNA 3103/4885L3MBTL1 1359/4885 |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | UGDH, IDH1, G6PD | PDE4A 2285/4885LMNA 3336/4885L3MBTL1 1574/4885 |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | GALE, UGGT1, DERA | PDE4A 3025/4885LMNA 2057/4885L3MBTL1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.